Serine Protease 3 Promotes Progression of Diffuse Large B-Cell Lymphoma and Serves as a Novel Prognostic Predictor

Table 2

Kaplan-Meier overall survival analyses.

Variables	Cases; ()	OS months ()	5-year OS (%)	value
Sex
Female	63		61.7%	0.218
Male	92		64.3%
Age
≤60 yrs	82		75.5%	0.002
>60 yrs	73		48.1%
B symptoms
Absence	95		75.2%	<0.001
Presence	60		42.7%
Ann Arbor stage
I-II	79		78.6%	<0.001
III-IV	76		45.5%
ECOG PS
0-1	114		75.2%	<0.001
≥2	41		26.7%
Serum LDH level
Normal	73		78.5%	<0.001
Elevated	82		48.2%
ENI
<2	102		69.6%	0.009
≥2	53		47.6%
Bulky tumor
No	120		66.8%	0.240
Yes	35		51.4%
IPI
0-2	106		76.6%	<0.001
3-5	49		31.1%
COO (Hans)
GCB	71		75.3%	0.020
ABC	84		51.6%
PRSS3 protein level
Low	74		77.2%	<0.001
High	81		49.4%

Abbreviations: PRSS3: serine protease 3; DLBCL: diffuse large B-cell lymphoma; ECOG PS: Eastern Cooperative Oncology Group performance status; LDH: lactate dehydrogenase; ENI: extra nodal involvement; IPI: International Prognostic Index; COO: cell-of-origin; GCB: germinal center B cell; ABC: activated B cell.